TRVI·Trevi Therapeutics, Inc.

TRVI closes its 15-session tracking window at $18.43 against the $19.72 reference, a complete -6.54% outcome; the fresh after-market quote is $18.51. The original post-reconstitution relief thesis had a technically strong start but no confirmed catalyst, and the subsequent fade, brief session-5 rebound, and failure to build the required higher low and tighter base left the recovery case unconfirmed. The Mesa's terminal judgment is that this episode is closed and no longer followed; one episode cannot establish a general edge.

TRVI is -13.34% after the regular session gave back the prior stabilization, leaving the recovery structure unconfirmed. The thesis needs a tighter base and higher low with visible demand; a further loss of the recent floor would invalidate the repair attempt.

TRVI is -9.76% in the regular open-settled capture, giving back the prior stabilization and leaving the recovery structure unconfirmed. The post-reconstitution case needs a higher low and tighter base with demand; a further loss of the recent floor would invalidate the repair attempt.

TRVI is +1.31% on the regular-session monitor, while the fresh Aftermarket quote is effectively flat at $18.14 (0.00%), leaving the relief move intact but unconfirmed. The post-reconstitution recovery still needs a tighter base and higher low with demand; without that structure, the tape has not regained durable credibility.

TRVI improved to -9.08% from -11.64% previously, but the regular-session rebound still finished near the bottom of its range and did not repair the continuation thesis. A tighter base with a higher low and better demand is still required before the tape can regain credibility.

TRVI deteriorated to -11.64% and remains below the scan reference, leaving the original continuation thesis unrepaired. The panel wants demand to build a tighter base rather than another reflex bounce; without that structure, the tape remains heavy and conviction stays low.

TRVI held its regular-session reclaim into Aftermarket, with the fresh quote at 17.91 confirming little additional drift from the close. The rebound has structure, but volume and healthcare breadth remain incomplete; a higher low above today's base is still the missing confirmation for continuation.

TRVI reclaimed VWAP and finished in the upper fifth of its range, lifting the tape to a 7.45% session gain and narrowing the loss to -9.71%. The rebound has structure, but volume stayed near average while healthcare breadth was red. The thesis is moving from damage toward repair; a higher low above today's base is the confirmation still missing.

TRVI remains under pressure at -9.71%, with no convincing reset visible in the session. The panel keeps the thesis on watch only for now: stabilization, a tighter base and renewed demand are required before continuation can be trusted.

TRVI remains under pressure at -16.23%, with no convincing reset visible in the open session. The panel keeps the thesis on watch only for now: stabilization, a tighter base and renewed demand are required before continuation can be trusted.

TRVI has no fresh premarket confirmation in this snapshot and remains under pressure relative to its scan reference. The panel sees no clean reset yet; stabilization and renewed demand are needed before the original thesis can regain traction.

TRVI is still 15.87% below the scan reference, so the original thesis has not been repaired. The panel wants better demand and a tighter base before trusting a new continuation attempt.

TRVI is still below the scan reference, so the original thesis is not yet repaired. The panel wants better demand and a tighter base before trusting the setup again, otherwise the tape still looks heavy.

TRVI remains below the scan reference, so the original thesis still needs repair rather than celebration. The panel wants to see a tighter base and improving demand before trusting the setup again; without that, the risk is that supply continues to define the range despite the earlier signal quality.

TRVI is still below the scan reference, and the tape has not supplied the follow-through needed to repair the early fade. The constructive case requires a tighter base and improving demand; otherwise, the unresolved risk is that supply continues to control the range.

TRVI has gone heavy after the initial move, giving back ground instead of building on the breakout. That leaves the burden on the next session to show whether this is just digestion or the start of a real momentum failure.

TRVI is acting heavy after the initial move, with the stock giving back ground instead of building on the breakout. That leaves the burden on the next session to decide whether this is just post-gap digestion or the market starting to price in a full momentum failure.

Session 2 check: TRVI is down -4.77%, slightly less weak than the first session but still below the scan price. The early tracking remains noisy, and the post should keep the focus on whether buyers can reclaim control.

Day 1 has slipped to -5.73%, which is early but meaningful enough to flag. It is a useful reminder that the first live sessions can still be noisy, and the post should keep that context visible.

Session 1 of 10 is at $18.59, down 5.73%, with SPY red and VIX elevated. The technical read is a modest pullback rather than a full breakdown, but day 1 still needs follow-through from buyers to keep the structure alive.

Session 0 of 10 is slightly below entry at $19.50 while SPY, QQQ, and the VIX backdrop are all less forgiving than ideal. The EMA stack and 97.67% of 52-week-high positioning are still in place, but day 0 needs follow-through rather than hope.

Day 0 (scan day) closed at \.52, a -1.02% fade from the scan price of \.69. The initial +9.69% session gain compressed toward the end of the day. RSI remains elevated; the pullback-to-EMA9 entry thesis is already starting to materialise.